Accessibility Menu
China Sxt Pharmaceuticals logo

China Sxt Pharmaceuticals

(NASDAQ) SXTC

Current Price$1.67
Market Cap$1.60M
Since IPO (2019)-100%
5 Year-100%
1 Year-99%
1 Month-19%

China Sxt Pharmaceuticals Financials at a Glance

Market Cap

$1.60M

Revenue (TTM)

$1.74M

Net Income (TTM)

-$3.30M

EPS (TTM)

-$35.49

P/E Ratio

-0.05

Dividend

$0.00

Beta (Volatility)

1.93 (High)

Price

$1.67

Volume

2,264

Open

$1.60

Previous Close

$1.67

Daily Range

$1.59 - $1.71

52-Week Range

$1.25 - $1,046.99

SXTC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About China Sxt Pharmaceuticals

Industry

Pharmaceuticals

Employees

75

CEO

Sze Beng Lim; Feng Zhou

Headquarters

Taizhou, 225300, CN

SXTC Financials

Key Financial Metrics (TTM)

Gross Margin

26%

Operating Margin

-2%

Net Income Margin

-3%

Return on Equity

-50%

Return on Capital

-10%

Return on Assets

-9%

Earnings Yield

-20.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.60M

Shares Outstanding

958.10K

Volume

2.26K

Avg. Volume

49.06K

Financials (TTM)

Gross Profit

$367.43K

Operating Income

-$2.68M

EBITDA

-$2.57M

Operating Cash Flow

-$2.35M

Capital Expenditure

-$2.02K

Free Cash Flow

-$2.35M

Cash & ST Invst.

$18.10M

Total Debt

$983.88K

China Sxt Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$455.71K

-7.8%

Gross Profit

$116.34K

-12.4%

Gross Margin

25.53%

N/A

Market Cap

$1.60M

N/A

Market Cap/Employee

$21.33K

N/A

Employees

75

N/A

Net Income

-$1.25M

-137.9%

EBITDA

-$1.01M

-127.6%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$19.96M

+131.0%

Accounts Receivable

$2.87M

+72.2%

Inventory

$751.35K

-52.7%

Long Term Debt

$158.26K

-46.9%

Short Term Debt

$1.04M

-89.1%

Return on Assets

-9.49%

N/A

Return on Invested Capital

-10.01%

N/A

Free Cash Flow

-$495.09K

+27.0%

Operating Cash Flow

-$494.08K

+26.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IXHLIncannex Healthcare Limited
$3.35-5.63%
ATLNAtlantic International Corp.
$1.50+7.91%
MISTMilestone Pharmaceuticals Inc.
$1.42-1.39%
IPHAInnate Pharma S.A.
$1.83+5.17%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$114.68-0.05%
SPCEVirgin Galactic
$6.18+0.36%
FFord Motor Company
$17.44+0.05%
SOFISoFi Technologies
$18.22+0.07%

Questions About SXTC

What is the current price of China Sxt Pharmaceuticals?

China Sxt Pharmaceuticals is trading at $1.67 per share.

What is the 52-week range for China Sxt Pharmaceuticals?

Over the past 52 weeks, China Sxt Pharmaceuticals has traded between $1.25 and $1,046.99.

How much debt does China Sxt Pharmaceuticals have?

As of the most recent reporting period, China Sxt Pharmaceuticals reported total debt of $983.88K.

How much cash does China Sxt Pharmaceuticals have on hand?

China Sxt Pharmaceuticals reported $18.13M in cash and cash equivalents in its most recent financial results.

What is China Sxt Pharmaceuticals’s dividend yield?

China Sxt Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.